158 related articles for article (PubMed ID: 1653493)
21. Application of monoclonal antibodies for the identification of the antigenic site for poliovirus neutralization.
Minor PD; Schild GC; Evans D; Ferguson M; Almond J
Dev Biol Stand; 1984; 57():171-5. PubMed ID: 6084608
[TBL] [Abstract][Full Text] [Related]
22. Monoclonal antibodies reactive with different sites of N and H antigenic particles of poliovirus.
Taniguchi K; Urasawa S; Urasawa T
J Gen Virol; 1983 Dec; 64 ( Pt 12)():2803-8. PubMed ID: 6198442
[TBL] [Abstract][Full Text] [Related]
23. Different virus-precipitating activities of neutralizing monoclonal antibodies that recognize distinct sites of poliovirus particles.
Taniguchi K; Urasawa S
Arch Virol; 1987; 92(1-2):27-40. PubMed ID: 2432854
[TBL] [Abstract][Full Text] [Related]
24. Analysis of the cloverleaf element in a human rhinovirus type 14/poliovirus chimera: correlation of subdomain D structure, ternary protein complex formation and virus replication.
Rieder E; Xiang W; Paul A; Wimmer E
J Gen Virol; 2003 Aug; 84(Pt 8):2203-2216. PubMed ID: 12867653
[TBL] [Abstract][Full Text] [Related]
25. Canyon rim residues, including antigenic determinants, modulate serotype-specific binding of polioviruses to mutants of the poliovirus receptor.
Harber J; Bernhardt G; Lu HH; Sgro JY; Wimmer E
Virology; 1995 Dec; 214(2):559-70. PubMed ID: 8553558
[TBL] [Abstract][Full Text] [Related]
26. Neutralization epitopes of human rhinovirus type 2.
Appleyard G; Russell SM; Clarke BE; Speller SA; Trowbridge M; Vadolas J
J Gen Virol; 1990 Jun; 71 ( Pt 6)():1275-82. PubMed ID: 1693662
[TBL] [Abstract][Full Text] [Related]
27. N-AgIB of poliovirus type 1: a discontinuous epitope formed by two loops of VP1 comprising residues 96-104 and 141-152.
Wiegers K; Uhlig H; Dernick R
Virology; 1989 Jun; 170(2):583-6. PubMed ID: 2471354
[TBL] [Abstract][Full Text] [Related]
28. Improved distribution of antigenic site specificity of poliovirus-neutralizing antibodies induced by a protease-cleaved immunogen in mice.
Roivainen M; Montagnon B; Chalumeau H; Murray M; Wimmer E; Hovi T
J Virol; 1990 Feb; 64(2):559-62. PubMed ID: 1688625
[TBL] [Abstract][Full Text] [Related]
29. Studies of the antigenic variation in poliovirus type 1. Selection and analysis of variant strains with monoclonal antibodies by neutralization.
Thibodeau L; Lacroix M; Lecomte J; Fauvel M
Dev Biol Stand; 1984; 57():157-63. PubMed ID: 6084606
[TBL] [Abstract][Full Text] [Related]
30. Antigenic structure of chimeras of type 1 and type 3 polioviruses involving antigenic sites 2, 3 and 4.
Minor PD; Ferguson M; Katrak K; Wood D; John A; Howlett J; Dunn G; Burke K; Almond JW
J Gen Virol; 1991 Oct; 72 ( Pt 10)():2475-81. PubMed ID: 1717641
[TBL] [Abstract][Full Text] [Related]
31. Growth phenotypes and biosafety profiles in poliovirus-receptor transgenic mice of recombinant oncolytic polio/human rhinoviruses.
Cello J; Toyoda H; Dejesus N; Dobrikova EY; Gromeier M; Wimmer E
J Med Virol; 2008 Feb; 80(2):352-9. PubMed ID: 18098139
[TBL] [Abstract][Full Text] [Related]
32. A new antigenic site of poliovirus recognized by an intertypic cross-neutralizing monoclonal antibody.
Uhlig J; Wiegers K; Dernick R
Virology; 1990 Oct; 178(2):606-10. PubMed ID: 2171198
[TBL] [Abstract][Full Text] [Related]
33. Poliovirus antigenic hybrids simultaneously expressing antigenic determinants from all three serotypes.
Murdin AD; Lu HH; Murray MG; Wimmer E
J Gen Virol; 1992 Mar; 73 ( Pt 3)():607-11. PubMed ID: 1372037
[TBL] [Abstract][Full Text] [Related]
34. An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies.
Evans DJ; McKeating J; Meredith JM; Burke KL; Katrak K; John A; Ferguson M; Minor PD; Weiss RA; Almond JW
Nature; 1989 Jun; 339(6223):385-8, 340. PubMed ID: 2542797
[TBL] [Abstract][Full Text] [Related]
35. The use of a monoclonal antibody and of DNA recombinant technology for the localization of a poliovirus neutralization epitope in viral capsid polypeptide VP1.
Bruneau P; van der Werf S; Wychowski C; Siffert O; Girard M
Dev Biol Stand; 1984; 57():177-85. PubMed ID: 6084609
[TBL] [Abstract][Full Text] [Related]
36. Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornavirus, human rhinovirus 14.
Sherry B; Mosser AG; Colonno RJ; Rueckert RR
J Virol; 1986 Jan; 57(1):246-57. PubMed ID: 2416951
[TBL] [Abstract][Full Text] [Related]
37. Interaction between the 5'-terminal cloverleaf and 3AB/3CDpro of poliovirus is essential for RNA replication.
Xiang W; Harris KS; Alexander L; Wimmer E
J Virol; 1995 Jun; 69(6):3658-67. PubMed ID: 7745714
[TBL] [Abstract][Full Text] [Related]
38. Revertants of poliovirus escape mutants: new insights into antigenic structures.
Ketterlinus R; Wiegers K; Dernick R
Virology; 1993 Feb; 192(2):525-33. PubMed ID: 8380664
[TBL] [Abstract][Full Text] [Related]
39. Translation and replication properties of the human rhinovirus genome in vivo and in vitro.
Todd S; Towner JS; Semler BL
Virology; 1997 Mar; 229(1):90-7. PubMed ID: 9123881
[TBL] [Abstract][Full Text] [Related]
40. Antigenic variation among 173 strains of type 3 poliovirus isolated in Finland during the 1984 to 1985 outbreak.
Huovilainen A; Kinnunen L; Ferguson M; Hovi T
J Gen Virol; 1988 Aug; 69 ( Pt 8)():1941-8. PubMed ID: 2841408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
